Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene.
Hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2) is a member of aldo-keto reductase superfamily, known to catalyze the inactivation of 17beta-hydroxysteroids to less active 17-keto forms and catalyze the conversion of 20alpha-hydroxyprogesterone to progesterone in vitro. To examine the role of HSD17B2 in vivo, we generated mice deficient in Hsd17b2 [HSD17B2 knockout (KO)] by a targeted gene disruption in embryonic stem cells. From the homozygous mice carrying the disrupted Hsd17b2, 70% showed embryonic lethality appearing at the age of embryonic d 11.5 onward. The embryonic lethality was associated with reduced placental size measured at embryonic d 17.5. The HSD17B2KO mice placentas presented with structural abnormalities in all three major layers: the decidua, spongiotrophoblast, and labyrinth. Most notable was the disruption of the spongiotrophoblast and labyrinthine layers, together with liquid-filled cysts in the junctional region and the basal layer. Treatments with an antiestrogen or progesterone did not rescue the embryonic lethality or the placenta defect in the homozygous mice. In hybrid background used, 24% of HSD17B2KO mice survived through the fetal period but were born growth retarded and displayed a phenotype in the brain with enlargement of ventricles, abnormal laminar organization, and increased cellular density in the cortex. Furthermore, the HSD17B2KO mice had unilateral renal degeneration, the affected kidney frequently appearing as a fluid-filled sac. Our results provide evidence for a role for HSD17B2 enzyme in the cellular organization of the mouse placenta.
Department of Physiology, Institute of Biomedicine, University of Turku, FIN-20520 Turku, Finland.
Pia
P
Rantakari
Leena
L
Strauss
Riku
R
Kiviranta
Heidi
H
Lagerbohm
Jenni
J
Paviala
Irma
I
Holopainen
Seppo
S
Vainio
Pirjo
P
Pakarinen
Matti
M
Poutanen
D015067:17-Hydroxysteroid Dehydrogenases; D000818:Animals; D001921:Brain / Q000002:abnormalities; D004958:Estradiol / Q000031:analogs & derivatives / Q000032:analysis / Q000494:pharmacology; D004960:Estradiol Dehydrogenases / Q000235:genetics* / Q000378:metabolism; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D005313:Fetal Death / Q000201:enzymology; D000077267:Fulvestrant; D006651:Histocytochemistry; D007668:Kidney / Q000002:abnormalities; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010920:Placenta / Q000002:abnormalities* / Q000201:enzymology*; D011247:Pregnancy; D013739:Testosterone / Q000032:analysis
D004965:Estrogen Antagonists; D000077267:Fulvestrant; D013739:Testosterone; D004958:Estradiol; D015067:17-Hydroxysteroid Dehydrogenases; C032690:3-alpha-(17-beta)-hydroxysteroid dehydrogenase (NAD(+)); D004960:Estradiol Dehydrogenases